TARO-TESTOSTERONE GEL

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

TESTOSTERONE

可用日期:

TARO PHARMACEUTICALS INC

ATC代码:

G03BA03

INN（国际名称）:

TESTOSTERONE

剂量:

1%

药物剂型:

GEL

组成:

TESTOSTERONE 1%

给药途径:

TRANSDERMAL

每包单位数:

2.5GX30

处方类型:

Schedule G (CDSA IV)

治疗领域:

ANDROGENS

產品總結:

Active ingredient group (AIG) number: 0106405004; AHFS:

授权状态:

APPROVED

授权日期:

2017-05-05

产品特点

Page 1 of 39
PRODUCT MONOGRAPH
TARO-TESTOSTERONE GEL
TESTOSTERONE GEL
1% W/W
ANDROGENS
FOR TOPICAL USE ONLY
Taro Pharmaceuticals Inc.
130 East Brampton,
Ontario L6T 1C1
Submission Control No: 243359 Date of Preparation: October 19, 2020
Page 2 of 39
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................... 3
SUMMARY PRODUCT INFORMATION
..........................................................................
3
INDICATIONS AND CLINICAL USE
................................................................................
3
CONTRAINDICATIONS
.....................................................................................................
4
WARNINGS AND PRECAUTIONS
....................................................................................
4
ADVERSE
REACTIONS....................................................................................................
11
DRUG INTERACTIONS
....................................................................................................
18
DOSAGE AND ADMINISTRATION
................................................................................
19
OVERDOSAGE
..................................................................................................................
21
ACTION AND CLINICAL PHARMACOLOGY
.............................................................. 21
STORAGE AND STABILITY
............................................................................................
24
SPECIAL HANDLING INSTRUCTIONS
.........................................................................
24
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................ 24
PART II: SCIENTIFIC INFORMATION
..................................................................................
26
PHARMACEUTICAL INFORMATION
............................................................................
26
CLINICAL TRIALS
........................................................................................